Syncona Limited (SYNC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Syncona Limited (SYNC) has a cash flow conversion efficiency ratio of 0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX5.88 Million ≈ $715.18 USD) by net assets (GBX1.02 Billion ≈ $124.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Syncona Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Syncona Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Syncona Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Syncona Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syncona Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avenir Telecom S.A
PA:AVT
|
-3.784x |
|
Gencell Ltd
TA:GNCL
|
-0.203x |
|
Craneware Plc
LSE:CRW
|
0.008x |
|
Altheora SA
PA:ALORA
|
0.089x |
|
Progressive Impact Corporation Bhd
KLSE:7201
|
0.361x |
|
Trio Petroleum Corp.
NYSE MKT:TPET
|
-0.060x |
|
cbdMD Inc
NYSE MKT:YCBD
|
-0.115x |
|
Pembangunan Graha Lestari Tbk
JK:PGLI
|
0.016x |
Annual Cash Flow Conversion Efficiency for Syncona Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Syncona Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Syncona Limited stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | GBX1.05 Billion ≈ $128.13K |
GBX43.91 Million ≈ $5.34K |
0.042x | +152.35% |
| 2024-03-31 | GBX1.24 Billion ≈ $150.74K |
GBX20.47 Million ≈ $2.49K |
0.017x | +7924.05% |
| 2023-03-31 | GBX1.25 Billion ≈ $152.66K |
GBX-265.00K ≈ $-32.24 |
0.000x | -205.59% |
| 2022-03-31 | GBX1.31 Billion ≈ $159.37K |
GBX262.00K ≈ $31.88 |
0.000x | +8769.65% |
| 2021-03-31 | GBX1.30 Billion ≈ $158.21K |
GBX-3.00K ≈ $-0.37 |
0.000x | -100.02% |
| 2020-03-31 | GBX1.25 Billion ≈ $151.67K |
GBX13.17 Million ≈ $1.60K |
0.011x | +5025.32% |
| 2019-03-31 | GBX1.46 Billion ≈ $177.05K |
GBX300.00K ≈ $36.50 |
0.000x | -97.34% |
| 2018-03-31 | GBX1.06 Billion ≈ $128.46K |
GBX8.19 Million ≈ $996.85 |
0.008x | -2.37% |
| 2017-03-31 | GBX895.24 Million ≈ $108.92K |
GBX7.12 Million ≈ $865.81 |
0.008x | -35.69% |
| 2016-03-31 | GBX472.25 Million ≈ $57.46K |
GBX5.84 Million ≈ $710.19 |
0.012x | +9.43% |
| 2015-03-31 | GBX479.06 Million ≈ $58.29K |
GBX5.41 Million ≈ $658.36 |
0.011x | +10.87% |
| 2014-03-31 | GBX434.85 Million ≈ $52.91K |
GBX4.43 Million ≈ $539.00 |
0.010x | +469.18% |
| 2013-03-31 | GBX229.61 Million ≈ $27.94K |
GBX-633.60K ≈ $-77.09 |
-0.003x | -- |
About Syncona Limited
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and… Read more